ConductScience.org, home

Paper42489754

Real-world study of effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients.

Qiu Y and 6 others. Eur J Clin Microbiol Infect Dis, 2026. Cited by 0 papers, by iCite.

Cite this record

ConductScience Library. Real-world study of effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients. Papers, record 42489754. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42489754

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Real-world study of effectiveness and safety compared among isavuconazole, amphotericin B, and voriconazole in invasive mold disease patients.
PubMed
Journal
Eur J Clin Microbiol Infect Dis
PubMed
Year
2026
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
0
iCite
Revised in PubMed
2026-07-23
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Qiu YYe
2Chen WSWu-Shu
3Li ZTZheng-Tu
4Li SQShao-Qiang
5Wang YYan
6Zhan YQYang-Qing
7Ye FFeng

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants6

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
NSFC82202544 & NSFC82270007the National Natural Science Foundation of ChinaPubMed
2023ZD0506200 & 2023ZD0506204the National Key Research and Development Program of ChinaPubMed
2021GXNSFBA220064Natural Science Foundation of Guangxi ProvincePubMed
202201020537the Science and Technology Program of GuangzhouPubMed
No. 2023M730801the China Postdoctoral Science FoundationPubMed
SKLRD- Z-202019the State Key Laboratory of Respiratory DiseasesPubMed

Source PubMed

Download CSV of grants

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128355466Invasive mould infections in the ICU setting: complexities and solutions.J Antimicrob Chemother2017https://conductscience.org/library/papers/28355466PubMed
228355467New pharmacological opportunities for the treatment of invasive mould diseases.J Antimicrob Chemother2017https://conductscience.org/library/papers/28355467PubMed
323729001Amphotericin B formulations: a comparative review of efficacy and toxicity.Drugs2013https://conductscience.org/library/papers/23729001PubMed
433333012Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance.Lancet Infect Dis2021https://conductscience.org/library/papers/33333012PubMed
531699664
Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium.
Lancet Infect Dis2019https://conductscience.org/library/papers/31699664PubMed
634882852Incidence, risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza: A systematic review and meta-analysis.Mycoses2022https://conductscience.org/library/papers/34882852PubMed
711801575Amphotericin B: spectrum and resistance.J Antimicrob Chemother2002https://conductscience.org/library/papers/11801575PubMed
824548001ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others.Clin Microbiol Infect2014https://conductscience.org/library/papers/24548001PubMed
926179012Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent.Clin Infect Dis2015https://conductscience.org/library/papers/26179012PubMed
1031802125
Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium.
Clin Infect Dis2020https://conductscience.org/library/papers/31802125PubMed
1112167683Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.N Engl J Med2002https://conductscience.org/library/papers/12167683PubMed
1235171022Safety and Effectiveness of Isavuconazole Treatment for Fungal Infections in Solid Organ Transplant Recipients (ISASOT Study).Microbiol Spectr2022https://conductscience.org/library/papers/35171022PubMed
1337300337A systematic review and meta-analysis of efficacy and safety of isavuconazole for the treatment and prophylaxis of invasive fungal infections.Mycoses2023https://conductscience.org/library/papers/37300337PubMed
1436530445Clinical research advances of isavuconazole in the treatment of invasive fungal diseases.Front Cell Infect Microbiol2022https://conductscience.org/library/papers/36530445PubMed
1512823944Antifungal agents: mechanisms of action.Trends Microbiol2003https://conductscience.org/library/papers/12823944PubMed
1635320642Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis.N Engl J Med2022https://conductscience.org/library/papers/35320642PubMed
1731279853Prediction models for voriconazole pharmacokinetics based on pharmacogenetics: AN exploratory study in a Spanish population.Int J Antimicrob Agents2019https://conductscience.org/library/papers/31279853PubMed
1829725999Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.Clin Pharmacokinet2018https://conductscience.org/library/papers/29725999PubMed
1930306415Isavuconazole Kinetic Exploration for Clinical Practice.Drugs R D2018https://conductscience.org/library/papers/30306415PubMed
2029570857Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.Mycoses2018https://conductscience.org/library/papers/29570857PubMed

See all 23 referencesDownload CSV of references

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Cited by
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/42489754

GET https://conductscience.org/api/papers/v1/42489754/references?page=2